Ameris Bancorp Q2 FY26 net income drops 53.19% to $51.4 million; net interest margin widens 11 basis points to 3.88%
Reuters2026/08/07 19:11- Ameris Bancorp posted Q2 net income available to common shareholders of $51.4 million, or $0.77 per diluted share, down from $109.8 million.
- Return on average assets fell to 0.73% from 1.65%, reflecting an $82.5 million litigation expense accrual tied to a California employment verdict.
- Tax-equivalent net interest income rose 8.89% to $253.4 million; net interest margin widened 11 basis points to 3.88%.
- Provision for credit losses climbed to $17.3 million from $2.8 million, while net charge-offs were $11.1 million, or 0.20% of average loans annualized.
- Noninterest income increased 6.7% to $73.5 million on a $7.4 million gain on securities, offset by a 17.1% drop in mortgage banking income to $32.5 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "copper rush" cools off? LME sees the largest delivery in nearly four weeks, copper price retreats to $14,000
Copper prices have stabilized around $14,000 per ton after previously falling, as exchange-tracked warehouses have experienced a new round of inventory deliveries, indicating that the supply shortage has somewhat eased.
Most panda coin types from the 2026 edition steadily rebounded in August
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
